# Development of Neutralizing Antibodies to Machupo Virus

> **NIH NIH R41** · ABWIZ BIO, INC. · 2024 · $280,769

## Abstract

PROJECT SUMMARY/ABSTRACT
In this Phase I STTR grant proposal, we will develop neutralizing antibodies against Machupo virus, a New World
arenavirus (NWA), by using an innovative, stabilized-trimer immunogen. Antibodies are thus far only known to
target the receptor-binding site. This novel immunogen will support discovery and characterization of neutralizing
antibodies against other critical sites in the pre-fusion conformation of the surface glycoprotein. This proposal
builds on the proof-of-concept for the related Lassa virus of the Arevirumab antibody cocktail, which combines
mAbs against both receptor-binding and fusion-blocking quaternary (trimer-bridging) epitopes to achieve late-
stage, low-dose in vivo protection.
Our approach involves utilizing advanced immunization techniques, an innovative stabilized antigen, and high-
throughput biotechnological screening to identify and characterize antibodies of complementary activities.
Provision of mAbs against complementary epitopes is also desired for development of cocktails that will prevent
mutagenic escape. The successful development of these antibodies in Phase I will set the foundation for Phase
II, where we plan to humanize and enhance the antibodies through sophisticated engineering, optimizing their
specificity and binding affinity to Machupo virus GPC. Additionally, Phase II will encompass preclinical
development, including efficacy and safety studies, to advance these antibodies towards clinical trials.
This project not only promises to advance our scientific understanding of Arenavirus pathogenesis but also aims
to develop a new class of therapeutics with potential commercial applications. Our goal is to bridge the gap from
laboratory research to clinical solutions, in line with NIH's mission to support innovative health research with
practical implications.

## Key facts

- **NIH application ID:** 11008445
- **Project number:** 1R41AI186830-01
- **Recipient organization:** ABWIZ BIO, INC.
- **Principal Investigator:** Toshiaki Maruyama
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $280,769
- **Award type:** 1
- **Project period:** 2024-08-06 → 2025-02-01

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11008445

## Citation

> US National Institutes of Health, RePORTER application 11008445, Development of Neutralizing Antibodies to Machupo Virus (1R41AI186830-01). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/11008445. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*